RT Journal Article
SR Electronic
T1 p38 MAPK inhibitors in COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3714
VO 40
IS Suppl 56
A1 Patricia Macedo
A1 Joann Rhodes
A1 Iain Kilty
A1 Peter Barnes
A1 Louise Donnelly
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P3714.abstract
AB p38 MAPK signalling upregulates inflammation and is known to be increased in COPD. This study investigated whether p38 inhibitors PF75 and PF32 suppressed release of inflammatory cytokines from macrophage-lineage cells.Peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages (MDM) were isolated from non-smokers (NS), smokers (S) and COPD patients. Cells were pre-treated with either p38 inhibitor or dexamethasone (DEX) prior to stimulation with LPS. Cell media was harvested at 24h and cytokine release (IL-6, CXCL8, IL-10 and TNF) measured by ELISA.Both p38 inhibitors and DEX suppressed cytokine release in a concentration-dependent manner in PBMC and MDM. There were no differences between subject groups.View this table:EC50 values (nM) for DEX, PF75 and PF32 on cytokine releasep38 inhibitors suppress release of inflammatory cytokines and may have a therapeutic role in COPD.